The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Siltuximab in Multicentric Castleman Disease

Anti-interleukin-6 antibody approved for HIV-negative HHV-8-negative idiopathic disease

Written by: Saygı Hospital Health Guide Editorial Board
Published:

This content is for general information; please consult your physician for diagnosis and treatment.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Hematoloji department. Book Appointment →

What is Siltuximab in Multicentric Castleman Disease?

Idiopathic multicentric Castleman disease is a polyclonal lymphoproliferative disorder driven by excess interleukin-6 signaling. Patients present with fevers, night sweats, weight loss, generalized lymphadenopathy, organomegaly, and laboratory evidence of acute-phase response and multilineage cytopenia.

Siltuximab binds circulating interleukin-6 with high affinity and prevents engagement of its receptor. The randomized phase II trial showed durable lymph node and symptomatic response in roughly one-third of patients with sustained benefit on long-term extension, while supportive care alone failed to control disease.

Therapy is continued long term in responders with monthly intravenous infusions. Adverse effects include infusion reactions, infections, and gastrointestinal symptoms. Tocilizumab, a related interleukin-6 receptor antibody, is an alternative used in regions where siltuximab is unavailable.

Symptoms

Persistent fever, night sweats, and weight loss
Generalized lymphadenopathy and splenomegaly
Anemia and hypoalbuminemia
Polyclonal hypergammaglobulinemia
Edema and ascites in severe disease

Risk Factors

Idiopathic disease without HIV or human herpesvirus 8
Active interleukin-6 driven inflammatory phenotype
Recurrent flares despite corticosteroid therapy
Elevated C-reactive protein and acute-phase reactants
Histology consistent with multicentric Castleman disease

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • When fevers and lymphadenopathy persist
  • When biopsy confirms Castleman disease histology
  • When organomegaly or cytopenia worsens
  • When steroid taper provokes flares
  • When tertiary referral is needed for therapy

Treatment Methods

01
Intravenous siltuximab every three weeks initially
02
Long-term maintenance dosing in responders
03
Tocilizumab in regions without siltuximab access
04
Adjunctive corticosteroids during flares
05
Rituximab and chemotherapy for refractory disease
06
Infection screening and immunoglobulin replacement when needed
07
Multidisciplinary review with hematology and infectious disease

Which Department to Visit?

You can visit our Hematoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Hematoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.